INDV Indivior Pharmaceuticals, Inc.

BULLISH Impact: 8/10 8-K
Horizon weeks Filed Apr 30, 2026 Processed 23d 15h ago SEC 0001193125-26-193925
8-K Item 2.02: Earnings release
Latest settled — T+5d
INDV ▲ +10.41% at T+5d
LONG call ✓ call won +10.41% · α vs SPY +8.69% · entry $36.78 → $40.61
Next anchor: T+20d in 5d
Last close $37.53 (close May 22) · +2.04% from $36.78 entry
Entry anchored
Apr 29, 03:59 PM ET
via Databento tick
T+1d
+2.39%
call +2.39% · α +2.17%
$37.66
settled 23d ago
T+5d
+10.41%
call +10.41% · α +8.69%
$40.61
settled 17d ago
T+20d
call — · α —
in 5d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Indivior reported Q1 2026 results with total net revenue of $317M (+19% YoY) and GAAP diluted EPS of $0.69, beating the consensus estimate of $0.64. The company raised its full-year 2026 guidance across all key metrics, including total net revenue to $1.215B-$1.285B and adjusted EBITDA to $620M-$660M (+50% YoY at midpoint). The strong beat and raised guidance are driven by accelerating SUBLOCADE net revenue (+32% YoY) and record quarterly adjusted EBITDA of $164M (+112% YoY).

Key Financial Metrics

Guidance
$1.215B-$1.285B
raised
Free Cash Flow
-$29.0M
Gross Margin
87.4%

Actionable Insight

The strong Q1 beat and raised guidance confirm accelerating SUBLOCADE momentum and operating leverage. With $275M remaining on the buyback and a strengthened balance sheet, the stock should re-rate higher. Monitor the Q2 dispense unit growth trajectory and any business development announcements as the company targets Phase III Breakout in H2 2026.

Key Facts

  • Q1 2026 total net revenue of $317M, up 19% YoY from $266M
  • Total SUBLOCADE net revenue of $232M, up 32% YoY from $176M
  • GAAP net income of $89M ($0.69 diluted EPS) vs $47M ($0.38) YoY
  • Non-GAAP net income of $123M ($0.96 diluted EPS) vs $56M ($0.45) YoY
  • Record quarterly adjusted EBITDA of $164M, up 112% YoY from $78M
  • Raised full-year 2026 guidance: net revenue $1.215B-$1.285B (from $1.125B-$1.195B)
  • Raised SUBLOCADE net revenue guidance to $950M-$990M (from $905M-$945M)
  • Raised adjusted EBITDA guidance to $620M-$660M (from $535M-$575M)
  • Repurchased ~4M shares for $125M in Q1; $275M remaining under $400M buyback program
  • Completed $500M convertible senior notes offering; repaid $333M term loan
  • Discontinued internal development of INDV-6001 and INDV-2000 pipeline assets

Financial Impact

Q1 revenue beat consensus by ~$44M (16%); EPS beat by ~$0.05 (7.8%); full-year guidance raised by $90M at midpoint for revenue and $85M for adjusted EBITDA

revenueepsebitdaguidanceshare buyback

Risk Factors

  • Pipeline setbacks with discontinuation of INDV-6001 and INDV-2000 reduce long-term growth optionality
  • SUBLOCADE faces eventual patent cliff starting 2031-2038
  • Operating cash flow was negative $9M in Q1 due to working capital timing; full-year guidance of ~$340M depends on execution
  • Convertible notes add $500M debt; dilution risk if shares convert

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-193925
Document: d40828dex993.htm0001193125-26-193925
Document: d40828dex992.htm0001193125-26-193925
Document: d40828d8k.htm0001193125-26-193925
Document: 0001193125-26-193925-index-headers.html0001193125-26-193925
Document: 0001193125-26-193925-index.html0001193125-26-193925
Document: 0001193125-26-193925.txt0001193125-26-193925
8-K Data (Synthetic)0001193125-26-193925
10 reports for INDV
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for INDV — sortable, filterable
Type Now
May 15, 2026
8d ago
8-K
NEUTRAL ★ 3/10
$36.77 awaiting T+5awaiting T+5$37.53 (+2.07%)
May 4, 2026
19d ago
8-K
NEUTRAL ★ 3/10
$38.98 $38.84▼ −0.36%▼ −3.30%$37.53 (−3.72%)
Apr 30, 2026
23d ago
8-K
BULLISH ★ 8/10
$36.78 $40.61▲ +10.41%▲ +8.69%$37.53 (+2.04%)
Apr 24, 2026
29d ago
Press Release
BULLISH ★ 7/10
$33.23 $36.78▲ +10.68%▲ +9.77%$37.53 (+12.94%)
Apr 9, 2026
6w ago
Press Release
NEUTRAL ★ 3/10
$32.31 $31.51▼ −2.48%▼ −5.66%$37.53 (+16.16%)
Mar 13, 2026
10w ago
8-K
NEUTRAL ★ 3/10
$31.11 $29.30▼ −5.82%▼ −3.70%$37.53 (+20.64%)
Mar 13, 2026
10w ago
Press Release
MIXED ★ 6/10
$31.11 $29.30▼ −5.82%▼ −3.70%$37.53 (+20.64%)
Mar 12, 2026
10w ago
8-K
NEUTRAL ★ 3/10
$30.86 $30.50▼ −1.17%▼ −0.19%$37.53 (+21.61%)
Mar 6, 2026
11w ago
Insider Cluster
NEUTRAL ★ 2/10
$32.27 $31.11▼ −3.59%▼ −2.07%$37.53 (+16.30%)
Feb 26, 2026
12w ago
8-K
BULLISH ★ 8/10
$33.71 $32.05▼ −4.92%▼ −3.80%$37.53 (+11.33%)
Showing 10 of 10

US Market Status

Market Closed — Opens Tue (35h 14m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access